Abstract
You can only predict things after they have happened. —Eugene Ionesco Is that really true? What is clear is that better surrogate end points are needed for follicular lymphoma (FL) clinical trials so we can predict outcomes before they actually occur; to this end, in this issue of Blood, Cottereau et al provide valuable direction.1 FL is the most common of the indolent non-Hodgkin lymphomas.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
